ASH 2018 Annual Meeting Highlights in Hodgkin Lymphoma
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: January 30, 2019
Expiration Date: January 30, 2020
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, participants will hear key highlights from a select group of abstracts of the most impactful data in Hodgkin lymphoma (HL) presented at the 2018 American Society of Hematology (ASH) 60th Annual Meeting. Leading experts in the field of HL will share their insights on a variety of abstracts, covering topics including, but not limited to: a detailed analysis from the Phase 3 ECHELON-1 study, the impact of PET-guided treatment on PFS, nivolumab for patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL), and a Phase 1 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with R/R HL. In addition, this activity will also cover brentuximab vedotin in combination with nivolumab in patients with R/R cHL and brentuximab vedotin in combination with chemotherapy for adolescents and young adults with Stage III or IV HL.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with Hodgkin lymphoma.
Upon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with Hodgkin lymphoma (HL)
- Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in HL
- Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in HL
Combination of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with RR HL – Catherine Diefenbach, MD
Nivolumab for RR cHL after Autologous Hematopoietic Cell Transplantation – Andreas Engert, MD
Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group – Andreas Engert, MD
Results of a Phase II Intergroup Trial on B-CAP in Older Patients with Advanced-Stage HL – Andreas Engert, MD
Detailed Analysis from the Phase 3 ECHELON-1 Study of Older Patients with Previously Untreated cHL – Andrew M. Evens, DO, MSc, FACP
Response-Adapted Therapy for Stage III/IV HL Demonstrates Limitation of PET-Adapted Approach – Andrew M. Evens, DO, MSc, FACP
Brentuximab Vedotin in Combination with Nivolumab or Chemotherapy in R/R Patients or AYA Patients – Julie M. Vose, MD, MBA
Instructions for Participation and Credit
This activity is eligible for credit through January 30, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Catherine Diefenbach, MD
Assistant Professor of Medicine
Clinical Director of Lymphoma
Department of Hematology/Oncology
NYU Langone Medical Center
New York, New York
Dr. Catherine Diefenbach received her medical degree from the University of Pennsylvania School of Medicine. She completed her internship and residency at the Johns Hopkins Hospital and her oncology fellowship at Memorial Sloan Kettering Cancer Center, where she spent an additional year focusing on translational immunology. Dr. Diefenbach is an Assistant Professor of Medicine, and the Clinical Director of Lymphoma in the Department of Hematology/Oncology at the NYU Langone Medical Center and a member of its Laura and Isaac Perlmutter Cancer Center. Additionally, she directs the lymphoma clinical research within the Hematology Division at the Perlmutter Cancer Center.
Dr. Diefenbach serves on the ECOG Lymphoma Committee, the Grants Committee of the ASCO Conquer the Cancer Foundation, the ASH Communications Committee, and is on the editorial board of Clinical Cancer Research. She is a translational physician-scientist specializing in the care of patients with Hodgkin and non-Hodgkin lymphoma, whose research is supported by the American Cancer Society, the National Cancer Institute (NCI), and the Doris Duke Foundation, and previously by the Lymphoma Research Foundation. Dr. Diefenbach’s scientific research focuses on the relationship between lymphoma and immunity; on developing novel and immune based treatment strategies for patients with relapsed lymphoma; and on biomarker discovery.
Andreas Engert, MD
Professor of Internal Medicine, Hematology, and Oncology
University Hospital of Cologne
Dr. Andreas Engert received his medical degree and completed his medical training at Hannover Medical School and the University Hospital of Cologne (Germany). He is a Professor of Internal Medicine, Hematology, and Oncology at University Hospital of Cologne, Germany. Dr. Engert worked at the Imperial Cancer Research Fund and the Royal Free Hospital in London, United Kingdom, on new immunotherapeutic approaches for cancer. He returned to Cologne to focus on developing antibody-based immunotherapy for patients with malignant lymphoma which resulted in a number of experimental phase I/II clinical trials. After he finished his postdoctoral lecture qualification, he was appointed Consultant and became Head of Staff. He then became Coordinating Editor of the Cochrane Hematological Malignancies Group (CHMG) and Vice Director of the Department for Hematology and Oncology.
In July 2017, Dr. Engert was appointed as editor-in-chief for the new EHA journal HemaSphere. He has published more than 400 original papers in journals such as The New England Journal of Medicine, The Lancet Oncology, Nature Genetics, Journal of Clinical Oncology, and others. He served as secretary and was elected chairman of the German Hodgkin Study Group (GHSG). He was elected as councilor to the European Hematology Association (EHA) Board of Directors and was treasurer from 2015 to 2018. The University of Belgrade awarded Dr. Engert an honorary doctorate. For his scientific work, he has received a number of awards including the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award, the Research Award of the University of Cologne, the award of the German Cancer Society, the Paul-Martini-Prize, and the John Ultmann Lymphoma Award.
Andrew M. Evens, DO, MSc, FACP
Professor of Medicine
Rutgers Robert Wood Johnson Medical Center
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Dr. Andrew Evens received his medical degree from Chicago College of Osteopathic Medicine and his MSc in clinical investigation from Northwestern University. He completed his internship and residency in internal medicine and his chief medical residency in medicine at Lutheran General Hospital in Illinois. Dr. Evens continued his postdoctoral studies with a fellowship in hematology/oncology at Northwestern University. He is a Professor of Medicine at Rutgers Robert Wood Johnson (RWJ) Medical Center, Associate Director for Clinical Services at Rutgers Cancer Institute of New Jersey, as well as Medical Director, Oncology Services at RWJ
Barnabas Health, New Brunswick, New Jersey.
Dr. Evens is American Board of Internal Medicine certified in internal medicine, hematology, and medical oncology. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the Eastern Cooperative Oncology Group. He is on the editorial boards of the American Journal of Blood Research, British Journal of Haematology, Leukemia, and the Journal of Clinical Oncology. Dr. Evens’ clinical expertise and research interests are dedicated to the field of lymphoma; he runs a translational laboratory studying the biology of lymphoma to discover new and novel treatments, which has resulted in publication of more than 350 research abstracts, book chapters, and peer-reviewed articles on this subject.
Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology/Hematology
University of Nebraska Medical Center
Dr. Julie Vose received her medical degree from the University of Nebraska Medical Center (UNMC) where she also completed her residency in internal medicine, served as chief resident, and completed a fellowship in hematology/oncology. In addition, she completed an MBA in health administration through the University of Colorado Business School in Denver. She is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at UNMC in Omaha.
Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as monoclonal antibodies, vaccine and cellular therapies, pathway-directed agents, and stem cell transplantation. She has published extensively on improvements in therapy and transplantation research which have added substantially to the research and knowledge base for the therapy of lymphoma. She was 2015/2016 president for the American Society of Clinical Oncology (ASCO).
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-19-002-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-002-093
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Catherine Diefenbach has received honoraria as a consultant from Bayer AG, Bristol-Myers Squibb Company, Genentech, Inc., Merck & Co., Inc., and Seattle Genetics, Inc. She has received grant support related to research activities from Bristol-Myers Squibb, Genentech, LAM Therapeutics, Inc., MEI Pharma Inc., Merck & Co., Millennium Pharmaceuticals, Inc., and Seattle Genetics. She owns significant holdings in Gilead.
Dr. Andres Engert has received honoraria as a consultant as well as grant support related to research activities from Affimed, Amgen Inc., Bristol-Myers Squibb Company, and Takeda Oncology.
Dr. Andrew Evens has received honoraria related to formal advisory activities from Affimed, Bayer AG, Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., Seattle Genetics, Inc., and Verastem, Inc. He has received grant support related to research activities from Merck & Co., Inc. and Takeda Oncology.
Dr. Julie Vose has received grant support related to research activities from Acerta Pharma, Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck & Co., Inc., Novartis AG, and Seattle Genetics, Inc. She has received consulting fees from AbbVie Inc., Acerta Pharma, Epizyme, Inc., F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals Inc., Karyopharm Therapeutics, Kite Pharma, Legend Biotech, Sandoz International GmbH, Nordic Nanovector ASA, Novartis, Pharmacyclics LLC, Vaniam Group, and Verastem, Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.